Brian McClune
Overview
Explore the profile of Brian McClune including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
778
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wagner C, Julian K, Bryan B, Steinbach M, Shewan S, Maxwell L, et al.
Leuk Lymphoma
. 2024 Jun;
65(9):1362-1365.
PMID: 38824620
No abstract available.
2.
Steinbach M, Neupane K, Aziz M, Lee-Smith W, Julian K, Godara A, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Sep;
24(1):15-22.
PMID: 37722944
Data on the disease course, presenting features, outcomes, and prognosis of younger patients with multiple myeloma (MM) are lacking. Younger patients with MM have historically been considered to have better...
3.
Bindal P, Najjar M, Koehn K, Godara A, Sborov D, McClune B, et al.
Leuk Lymphoma
. 2023 May;
64(7):1340-1343.
PMID: 37170589
No abstract available.
4.
Etekal T, Koehn K, Sborov D, McClune B, Prasad V, Haslam A, et al.
Br J Haematol
. 2022 Dec;
200(5):587-594.
PMID: 36495317
Use of surrogate end-points such as progression-free survival (PFS) and other time-to-event (TTE) end-points is common in multiple myeloma (MM) clinical trials. This systematic review characterises all published randomised controlled...
5.
Vardell V, Ermann D, Tantravahi S, Haaland B, McClune B, Godara A, et al.
Am J Hematol
. 2022 Oct;
98(1):41-48.
PMID: 36266759
Treatment at academic cancer centers (ACs) is associated with improved survival across hematologic malignancies, though the benefit in multiple myeloma (MM) has not been examined. This study aims to evaluate...
6.
Mohyuddin G, Ahlstrom J, Chmielewski C, Sweeney N, Molina T, Cheung C, et al.
Lancet Haematol
. 2022 Sep;
9(10):e716-e719.
PMID: 36174636
No abstract available.
7.
McInturf G, Younger K, Sanchez C, Walde C, Abdallah A, Ahmed N, et al.
Eur J Haematol
. 2022 Sep;
109(5):559-565.
PMID: 36054450
Introduction: Despite treatment advances, multiple myeloma (MM) remains a significant source of morbidity and mortality. We aimed to examine specialist palliative care (SPC) involvement and end-of-life care for patients with...
8.
Gil K, Abbasi S, Mehta K, McClune B, Sborov D, Ahmed N, et al.
Clin Hematol Int
. 2022 Aug;
4(1-2):56-59.
PMID: 35950203
No abstract available.
9.
Steinbach M, Julian K, McClune B, Sborov D
Ther Adv Hematol
. 2022 Jul;
13:20406207221100659.
PMID: 35860442
The therapeutic options available for patients with multiple myeloma have greatly expanded over the past decade and incorporating these novel agents into routine clinical practice has significantly improved outcomes. The...
10.
Ouchveridze E, Banerjee R, Desai A, Aziz M, Lee-Smith W, Mian H, et al.
Blood Cancer J
. 2022 Apr;
12(4):74.
PMID: 35459862
Hematologic malignancy outcomes have remarkably improved in the past decade with further advancement expected in future years. However, the detrimental effects of financial toxicity (FT) on patients with hematologic malignancies,...